Literature DB >> 8163700

Inhibition of fibrin monomer polymerisation by myeloma immunoglobulin.

M J O'Kane1, G B Wisdom, Z R Desai, G P Archbold.   

Abstract

Myelomatosis was diagnosed in a 64 year old man on the basis of a serum paraprotein band (type IgG lambda, 42 g/l), plasma cell infiltration of bone marrow, and multiple lytic lesions evident on skull x ray picture. Blood specimens taken into plain glass tubes showed bulky gelatinous clot formation with minimal clot retraction. Coagulation tests were significantly abnormal with an increase in thrombin time, prothrombin time, and reptilase time. The possibility that the paraprotein was interfering with fibrin production was investigated. The rate of fibrin monomer polymerisation (measured turbidometrically) was reduced in patient plasma compared with control plasma. Although purified fibrin monomer prepared from the patient's fibrinogen polymerised normally, the addition of purified paraprotein caused a dose dependent reduction in the rate of polymerisation. These results suggest that the paraprotein was impairing fibrin formation by inhibiting fibrin monomer polymerisation. After chemotherapy the paraprotein concentration decreased and the coagulation results returned to normal.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8163700      PMCID: PMC501909          DOI: 10.1136/jcp.47.3.266

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  8 in total

1.  Inhibition of conversion of fibrinogen to fibrin by abnormal proteins in multiple myeloma.

Authors:  P G FRICK
Journal:  Am J Clin Pathol       Date:  1955-11       Impact factor: 2.493

Review 2.  The normal and morbid biology of fibrinogen.

Authors:  C V Dang; W R Bell; M Shuman
Journal:  Am J Med       Date:  1989-11       Impact factor: 4.965

3.  Dysfibrinogenemia associated with liver disease.

Authors:  J E Palascak; J Martinez
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

4.  Antibody activity of human myeloma globulins.

Authors:  M Seligmann; J C Brouet
Journal:  Semin Hematol       Date:  1973-04       Impact factor: 3.851

5.  Inhibition of fibrin monomer polymerization by lambda myeloma globulins.

Authors:  M Coleman; E M Vigliano; M E Weksler; R L Nachman
Journal:  Blood       Date:  1972-02       Impact factor: 22.113

6.  Hereditary dysfibrinogenemia.

Authors:  T C Bithell
Journal:  Clin Chem       Date:  1985-04       Impact factor: 8.327

7.  Fibrinogen Bethesda: a congenital dysfibrinogenemia with delayed fibrinopeptide release.

Authors:  H R Gralnick; H M Givelber; J R Shainoff; J S Finlayson
Journal:  J Clin Invest       Date:  1971-09       Impact factor: 14.808

8.  A naturally occurring antibody that inhibits fibrin polymerization.

Authors:  W K Hoots; N A Carrell; R H Wagner; H A Cooper; J McDonagh
Journal:  N Engl J Med       Date:  1981-04-09       Impact factor: 91.245

  8 in total
  2 in total

1.  Dysfibrinogenemia with Subgaleal Hematoma: An Unusual Presentation.

Authors:  Manika Khare; Vijay Kumar; Sadhna Marwah; A S Nigam; Gurdeep Buxi
Journal:  Indian J Hematol Blood Transfus       Date:  2015-10-26       Impact factor: 0.900

2.  Interference of M-protein on prothrombin time test - case report.

Authors:  Sandra Margetić; Ivana Ćelap; Lora Dukić; Ines Vukasović; Lucija Virović-Jukić
Journal:  Biochem Med (Zagreb)       Date:  2016       Impact factor: 2.313

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.